[
    {
        "file": "outcomeinfo_PICO4a.json",
        "outcome uid": "c463b84c",
        "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine",
        "comparator": " No pharmacological treatment ",
        "outcome": "Mortality",
        "paper_data": {
            "50df60b4": {
                "label_comparator_data": {
                    "raw_data": "3.3% (placebo)"
                },
                "label_intervention_data": {
                    "raw_data": "5.1% (quetiapine 200 mg/day), 7.3% (queti- apine 100 mg/day)"
                }
            },
            "0643f463": {
                "label_comparator_data": {
                    "event": [
                        "3"
                    ],
                    "total": [
                        "142"
                    ],
                    "no_event": [
                        "139"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "5"
                    ],
                    "total": [
                        "279"
                    ],
                    "no_event": [
                        "274"
                    ]
                }
            },
            "44c2f905": {
                "label_comparator_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "31"
                    ],
                    "no_event": [
                        "31"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "1"
                    ],
                    "total": [
                        "31"
                    ],
                    "no_event": [
                        "30"
                    ]
                }
            },
            "d21566cc": {
                "label_comparator_data": {
                    "event": [
                        "4"
                    ],
                    "total": [
                        "170"
                    ],
                    "no_event": [
                        "166"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "6"
                    ],
                    "total": [
                        "167"
                    ],
                    "no_event": [
                        "161"
                    ]
                }
            }
        },
        "population": "Patients with dementia and agitation/aggressive behavior ",
        "outcome_type": "Dichotomous Data"
    },
    {
        "file": "outcomeinfo_PICO4a.json",
        "outcome uid": "e0b56f32",
        "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine",
        "comparator": " No pharmacological treatment ",
        "outcome": "Agitation/aggression",
        "data_type": "Continuous Data",
        "paper_data": {
            "50df60b4": {
                "total": 2,
                "corrected": 0,
                "label_comparator_data": "-2.5 (SD 0.9)",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "73",
                        "Insufficient evidence to draw a conclusion",
                        "92",
                        "47"
                    ],
                    "mean": [
                        "Insufficient evidence to draw a conclusion",
                        "19.4 (SD 9.9)"
                    ]
                },
                "label_intervention_data": "Intervention 1: - 2.5 (0.9); intervention 2: -1.8 (0.8)",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "114",
                        "120",
                        "333",
                        "234",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "Quetiapine 200 mg/day: Baseline mean=18.4 (SD=8.4)",
                        "Quetiapine 200 mg/day: Baseline mean = 18.4, SD = 8.4",
                        "Quetiapine 100 mg/day: Baseline mean=18.3 (SD=8.2)",
                        "Quetiapine 100 mg/day: Baseline mean = 18.3, SD = 8.2",
                        "Placebo: Baseline mean = 19.4, SD = 9.9",
                        "Quetiapine 100 mg/day: Baseline mean = 18.3 (SD 8.2)",
                        "Quetiapine 200 mg/day: Baseline mean = 18.4 (SD 8.4)",
                        "Placebo: Baseline mean = 19.4 (SD 9.9)",
                        "Placebo: Baseline mean=19.4 (SD=9.9)",
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            },
            "f5076959": {
                "total": 2,
                "corrected": 0,
                "label_comparator_data": "-2.1 (SD 4.6)",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "52",
                        "50",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "3.7\u00b110",
                        "Insufficient evidence to draw a conclusion"
                    ]
                },
                "label_intervention_data": "Intervention 1: -4.1 (3.7) Intervention 2: -3.9 (4.2) Intervention 3: -3.1 (4.1) ",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "159",
                        "Insufficient evidence to draw a conclusion",
                        "206"
                    ],
                    "mean": [
                        "Insufficient evidence to draw a conclusion for aripiprazole, zoleptil, quetiapine, and clozapine",
                        "7.6 \u00b1 7.7 for olanzapine 5 mg/d",
                        "7.6 \u00b1 7.7 (5 mg/d olanzapine)",
                        "Aggression scores significantly improved for risperidone, but specific values are not provided.",
                        "3.7 \u00b1 10.0 (placebo)",
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            },
            "44c2f905": {
                "total": 2,
                "corrected": 1,
                "label_comparator_data": "-9.0 (16.5)",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "20\u201321",
                        "21",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "At 6 weeks: Mean change = +6.2, SD = 17.6",
                        "At 26 weeks: Mean change = -9.0, SD = 16.5",
                        "Insufficient evidence to draw a conclusion"
                    ]
                },
                "label_intervention_data": "-8.1 (12.7)",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "20\u201321",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            },
            "d21566cc": {
                "total": 2,
                "corrected": 0,
                "label_comparator_data": "-3.1",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "72, 79",
                        "167",
                        "27",
                        "72",
                        "79",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "Insufficient evidence to draw a conclusion"
                    ]
                },
                "label_intervention_data": "-7.5",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "72, 81, 87",
                        "39",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            }
        }
    },
    {
        "file": "outcomeinfo_PICO4a.json",
        "outcome uid": "9fbb3c56",
        "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine",
        "comparator": " No pharmacological treatment ",
        "outcome": "Global cognitive function",
        "data_type": "Continuous Data",
        "paper_data": {
            "f5076959": {
                "label_comparator_data": "-0.3 (2.2) ",
                "pred1_comparator_data": {
                    "data_type": "Not Applicable"
                },
                "label_intervention_data": "Intervention 1: -0.5 (3.3); Intervention 2: -1 (3.1); Intervention 3: -0.3 (2.2) ",
                "pred1_intervention_data": {
                    "data_type": "Not Applicable"
                }
            },
            "c6e3bcaf": {
                "total": 2,
                "corrected": 0,
                "label_comparator_data": "-0.7 (2.7) ",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "Insufficient evidence to draw a conclusion"
                    ]
                },
                "label_intervention_data": "Intervention 1: -0.1 (3.7); Intervention 2: -0.8 (3.8); Intervention 3: -0.8 (3.2)",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "421",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            },
            "44c2f905": {
                "total": 2,
                "corrected": 2,
                "label_comparator_data": "3.3 (17.4) ",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "20-21",
                        "18",
                        "19",
                        "20\u201321",
                        "21",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "Mean change = +3.3 (SD 17.4, n=19) at 26 weeks",
                        "Mean change = +3.2 (SD 15.1, n=18) at 6 weeks",
                        "Mean change at 6 weeks: 3.2, SD: 15.1",
                        "Insufficient evidence to draw a conclusion",
                        "Mean change at 26 weeks: 3.3, SD: 17.4"
                    ]
                },
                "label_intervention_data": "-11.3 (15.6)",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "Insufficient evidence to draw a conclusion",
                        "61"
                    ],
                    "mean": [
                        "Quetiapine: Mean change = -11.3 (SD 15.6) at 26 weeks",
                        "Quetiapine: Mean change = -10.5 (SD 14.8) at 6 weeks",
                        "Quetiapine: -11.3 (SD 15.6) at 26 weeks",
                        "Insufficient evidence to draw a conclusion for aripiprazole, zoleptil, olanzapine, risperidone, or clozapine",
                        "Quetiapine: -10.5 (SD 14.8) at 6 weeks; -11.3 (SD 15.6) at 26 weeks",
                        "Insufficient evidence to draw a conclusion for other interventions (aripiprazole, zoleptil, olanzapine, risperidone, clozapine)",
                        "Quetiapine 6 weeks: -10.5 (SD 14.8)",
                        "Quetiapine: -10.5 (SD 14.8) at 6 weeks",
                        "Quetiapine 26 weeks: -11.3 (SD 15.6)",
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            }
        }
    },
    {
        "file": "outcomeinfo_PICO4a.json",
        "outcome uid": "5920def2",
        "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine",
        "comparator": " No pharmacological treatment ",
        "outcome": "SAEs",
        "paper_data": {
            "50df60b4": {
                "label_comparator_data": {
                    "event": [
                        "9"
                    ],
                    "total": [
                        "92"
                    ],
                    "no_event": [
                        "83"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "21"
                    ],
                    "total": [
                        "241"
                    ],
                    "no_event": [
                        "220"
                    ]
                }
            },
            "baf84590": {
                "label_comparator_data": {
                    "event": [
                        "2"
                    ],
                    "total": [
                        "20"
                    ],
                    "no_event": [
                        "18"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "2"
                    ],
                    "total": [
                        "20"
                    ],
                    "no_event": [
                        "18"
                    ]
                }
            },
            "0643f463": {
                "label_comparator_data": {
                    "event": [
                        "19"
                    ],
                    "total": [
                        "142"
                    ],
                    "no_event": [
                        "123"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "40"
                    ],
                    "total": [
                        "279"
                    ],
                    "no_event": [
                        "239"
                    ]
                }
            },
            "d21566cc": {
                "label_comparator_data": {
                    "event": [
                        "15"
                    ],
                    "total": [
                        "170"
                    ],
                    "no_event": [
                        "155"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "28"
                    ],
                    "total": [
                        "167"
                    ],
                    "no_event": [
                        "139"
                    ]
                }
            }
        },
        "population": "Patients with dementia and agitation/aggressive behavior ",
        "outcome_type": "Dichotomous Data"
    },
    {
        "file": "outcomeinfo_PICO4b.json",
        "outcome uid": "b36ddbfc",
        "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine",
        "comparator": "Haloperidol",
        "outcome": "Mortality",
        "paper_data": {
            "2271541c": {
                "label_comparator_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "60"
                    ],
                    "no_event": [
                        "60"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "60"
                    ],
                    "no_event": [
                        "60"
                    ]
                }
            },
            "793447a7": {
                "label_comparator_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "28"
                    ],
                    "no_event": [
                        "28"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "30"
                    ],
                    "no_event": [
                        "30"
                    ]
                }
            },
            "8c317dba": {
                "label_comparator_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "29"
                    ],
                    "no_event": [
                        "29"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "29"
                    ],
                    "no_event": [
                        "29"
                    ]
                }
            }
        },
        "population": "Patients with dementia and agitation/aggressive behavior ",
        "outcome_type": "Dichotomous Data"
    },
    {
        "file": "outcomeinfo_PICO4b.json",
        "outcome uid": "19c9b59e",
        "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine",
        "comparator": "Haloperidol",
        "outcome": "Agitation/aggression",
        "data_type": "Continuous Data",
        "paper_data": {
            "8c317dba": {
                "total": 2,
                "corrected": 2,
                "label_comparator_data": "-10",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "28",
                        "29"
                    ],
                    "mean": [
                        "10.0",
                        "Insufficient evidence to draw a conclusion",
                        "36.34 \u00b1 10.4"
                    ]
                },
                "label_intervention_data": "-8.1",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "29",
                        "27"
                    ],
                    "mean": [
                        "Haloperidol group: BEHAVE-AD aggressiveness score reduction = statistically significant (p < 0.011)",
                        "Baseline CMAI: 48.94 \u00b1 14.5",
                        "Insufficient evidence to draw a conclusion for aripiprazole, zoleptil, olanzapine, quetiapine, or clozapine",
                        "Risperidone group: BEHAVE-AD aggressiveness score reduction = statistically significant (p < 0.019)",
                        "Risperidone: 40.8 \u00b1 16.9",
                        "Haloperidol group: CMAI total score reduction = 10.0 (p < 0.001)",
                        "Endpoint Aggressiveness: 0.9 \u00b1 2.0",
                        "Risperidone group: CMAI total score reduction = 8.1 (p < 0.002)",
                        "Risperidone: CMAI Score (Endpoint) - 40.8 \u00b1 16.9",
                        "Endpoint CMAI: 40.8 \u00b1 16.9",
                        "Baseline Aggressiveness: 2.2 \u00b1 2.5",
                        "Insufficient evidence to draw a conclusion",
                        "Risperidone: Aggressiveness Score (Endpoint) - 0.9 \u00b1 2.0"
                    ]
                }
            },
            "64979d7f": {
                "total": 2,
                "corrected": 1,
                "label_comparator_data": "-3.6",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "344",
                        "81",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "Mean reduction in BEHAVE-AD total score at endpoint: -6.6",
                        "BEHAVE-AD Aggressiveness Subscore: Haloperidol mean outcome value = -1.6",
                        "CMAI Physical Aggression: Haloperidol mean outcome value = -2.3",
                        "Insufficient evidence to draw a conclusion for standard deviation",
                        "Insufficient evidence to draw a conclusion on standard deviation",
                        "CMAI Verbal Aggression: Haloperidol mean outcome value = -1.0",
                        "CMAI Verbal Aggression at Endpoint: -1.0",
                        "CMAI Physical Aggression at Endpoint: -2.3",
                        "Insufficient evidence to draw a conclusion",
                        "BEHAVE-AD Aggressiveness Subscore at Endpoint: -1.6"
                    ]
                },
                "label_intervention_data": "-8.3",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "115",
                        "344",
                        "68",
                        "Insufficient evidence to draw a conclusion"
                    ],
                    "mean": [
                        "Endpoint: Risperidone \u22125.2 (no SD), Haloperidol \u22126.6 (no SD), Placebo +4.2 (no SD)",
                        "Endpoint (Physical Aggression): Risperidone 2.7 (no SD), Haloperidol \u22122.3 (no SD), Placebo \u22120.7 (no SD)",
                        "Mean outcome value (aggression) for risperidone at endpoint: -1.7",
                        "BEHAVE-AD total score reduction at endpoint: risperidone \u22125.2, haloperidol \u22126.6, placebo 4.2",
                        "Physical aggression endpoint score: risperidone 2.7, haloperidol \u22122.3, placebo \u22120.7",
                        "BEHAVE-AD aggressiveness score reduction at endpoint: risperidone 34%, placebo 16%",
                        "Week 12 (Physical Aggression): Risperidone \u22125.9 (no SD), Placebo \u22123.5 (no SD)",
                        "CMAI physical aggression score reduction at endpoint: risperidone 34%, placebo 8%",
                        "Mean outcome value (aggression) for risperidone at week 12: -2.9",
                        "BEHAVE-AD Total Scores at endpoint: Risperidone \u22125.2, Placebo +4.2",
                        "BEHAVE-AD Total Scores at week 12: Risperidone \u22128.6, Placebo \u22126.2",
                        "Physical Aggression Scores at week 12: Risperidone \u22125.9, Placebo \u22123.5",
                        "Risperidone: -8.3 (CMAI Total Aggression at week 12)",
                        "CMAI Total Aggression Scores at week 12: Risperidone \u22128.3, Placebo \u22124.9",
                        "Endpoint (Aggressiveness Subscore): Risperidone \u22121.7 (no SD), Haloperidol \u22121.6 (no SD), Placebo \u22120.8 (no SD)",
                        "CMAI total aggressiveness score reduction at endpoint: risperidone 34%, placebo 12%",
                        "Endpoint (Verbal Aggression): Risperidone \u22121.0 (no SD), Haloperidol \u22121.0 (no SD), Placebo \u22120.8 (no SD)",
                        "Week 12: Risperidone \u22128.6 (no SD), Placebo \u22126.2 (no SD)",
                        "BEHAVE-AD Aggressiveness Subscores at endpoint: Risperidone \u22121.7, Placebo \u22120.8",
                        "Risperidone: -5.2 (BEHAVE-AD Total Scores at endpoint)",
                        "Week 12 (Total Aggression): Risperidone \u22128.3 (no SD), Placebo \u22124.9 (no SD)",
                        "Insufficient evidence to draw a conclusion",
                        "CMAI verbal aggression score reduction at endpoint: risperidone 32%, placebo 17%",
                        "Week 12 (Aggressiveness Subscore): Risperidone \u22122.9 (no SD), Placebo \u22121.5 (no SD)",
                        "Risperidone: -1.7 (BEHAVE-AD Aggressiveness Subscore at endpoint)",
                        "Verbal Aggression Scores at endpoint: Risperidone \u22121.0, Placebo \u22120.8",
                        "Standard deviation: Insufficient evidence to draw a conclusion"
                    ]
                }
            }
        }
    },
    {
        "file": "outcomeinfo_PICO4b.json",
        "outcome uid": "9394e2f2",
        "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine",
        "comparator": "Haloperidol",
        "outcome": "Global cognitive function",
        "data_type": "Continuous Data",
        "paper_data": {
            "793447a7": {
                "total": 2,
                "corrected": 1,
                "label_comparator_data": "-0.13",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "28"
                    ],
                    "mean": [
                        "10.9 \u00b1 7.2",
                        "Insufficient evidence to draw a conclusion",
                        "10.9",
                        "7.2"
                    ]
                },
                "label_intervention_data": "0.53",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "30",
                        "Insufficient evidence to draw a conclusion",
                        "60"
                    ],
                    "mean": [
                        "Haloperidol: Mean=-0.13, Standard Deviation=Not provided",
                        "Olanzapine: +0.53",
                        "Olanzapine: Mean=+0.53, Standard Deviation=Not provided",
                        "Haloperidol: -0.13",
                        "Olanzapine: +0.53, Haloperidol: -0.13",
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            },
            "8c317dba": {
                "total": 2,
                "corrected": 1,
                "label_comparator_data": "-0.15",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "31",
                        "Insufficient evidence to draw a conclusion",
                        "28",
                        "29"
                    ],
                    "mean": [
                        "-0.15",
                        "8.2 \u00b1 5.0"
                    ]
                },
                "label_intervention_data": "-0.42",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "27",
                        "Insufficient evidence to draw a conclusion",
                        "58",
                        "29"
                    ],
                    "mean": [
                        "Overall: 8.0 \u00b1 5.5",
                        "8.2 \u00b1 5.0 for Haloperidol",
                        "Risperidone: 7.9 \u00b1 6.0.",
                        "7.9 \u00b1 6.0 for Risperidone",
                        "8.0 \u00b1 5.5 Overall",
                        "Haloperidol: 8.2 \u00b1 5.0",
                        "Risperidone: 7.9, \u00b16.0",
                        "Insufficient evidence to draw a conclusion",
                        "Risperidone: 7.9 \u00b1 6.0"
                    ]
                }
            }
        }
    },
    {
        "file": "outcomeinfo_PICO4b.json",
        "outcome uid": "c44985bf",
        "intervention": "Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine",
        "comparator": "Haloperidol",
        "outcome": "Serious adverse events",
        "paper_data": {
            "2271541c": {
                "label_comparator_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "60"
                    ],
                    "no_event": [
                        "60"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "60"
                    ],
                    "no_event": [
                        "60"
                    ]
                }
            }
        },
        "population": "Patients with dementia and agitation/aggressive behavior ",
        "outcome_type": "Dichotomous Data"
    },
    {
        "file": "outcomeinfo_PICO4c.json",
        "outcome uid": "d9b623af",
        "intervention": "Discontinuation of antipsychotics",
        "comparator": "Continuation of treatment",
        "outcome": "Mortality",
        "paper_data": {
            "39351825": {
                "label_comparator_data": {
                    "event": [
                        "1"
                    ],
                    "total": [
                        "28"
                    ],
                    "no_event": [
                        "27"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "3"
                    ],
                    "total": [
                        "27"
                    ],
                    "no_event": [
                        "24"
                    ]
                }
            },
            "7e48dccc": {
                "label_comparator_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "14"
                    ],
                    "no_event": [
                        "14"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "22"
                    ],
                    "no_event": [
                        "22"
                    ]
                }
            },
            "8f835918": {
                "label_comparator_data": {
                    "event": [
                        "1"
                    ],
                    "total": [
                        "70"
                    ],
                    "no_event": [
                        "69"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "1"
                    ],
                    "total": [
                        "40"
                    ],
                    "no_event": [
                        "39"
                    ]
                }
            },
            "c57b6880": {
                "label_comparator_data": {
                    "event": [
                        "3"
                    ],
                    "total": [
                        "54"
                    ],
                    "no_event": [
                        "51"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "3"
                    ],
                    "total": [
                        "46"
                    ],
                    "no_event": [
                        "43"
                    ]
                }
            },
            "aead9e3a": {
                "label_comparator_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "10"
                    ],
                    "no_event": [
                        "10"
                    ]
                },
                "label_intervention_data": {
                    "event": [
                        "0"
                    ],
                    "total": [
                        "10"
                    ],
                    "no_event": [
                        "10"
                    ]
                }
            }
        },
        "population": "Patients dementia who are currently being treated with anti-psychotics",
        "outcome_type": "Dichotomous Data"
    },
    {
        "file": "outcomeinfo_PICO4c.json",
        "outcome uid": "401a51cf",
        "intervention": "Discontinuation of antipsychotics",
        "comparator": "Continuation of treatment",
        "outcome": "Neuropsychiatric symptoms",
        "data_type": "Continuous Data",
        "paper_data": {
            "39351825": {
                "total": 2,
                "corrected": 2,
                "label_comparator_data": "-1.79 (4.9)",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "28"
                    ],
                    "mean": [
                        "Depression: Baseline - 18 (SD not reported), Week 4 - 12 (SD not reported)",
                        "+1.79 (SD=4.9)",
                        "Anxiety: Baseline - 18 (SD not reported), Week 4 - 12 (SD not reported)",
                        "4.9",
                        "Mean outcome value: +1.79",
                        "1.79",
                        "Delusions: Baseline - 10 (SD 6), Week 4 - 5 (SD 4)",
                        "Standard deviation: 4.9",
                        "Agitation/Aggression: Baseline - 14 (SD not reported), Week 4 - 14 (SD not reported)",
                        "+1.79, 4.9",
                        "Insufficient evidence to draw a conclusion"
                    ]
                },
                "label_intervention_data": "-0.19 (5.3)",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "Insufficient evidence to draw a conclusion",
                        "24",
                        "27"
                    ],
                    "mean": [
                        "Depression - Week 4 - Mean: 8",
                        "Agitation: +0.37 (2.6)",
                        "Anxiety - Week 4 - Mean: 11",
                        "Agitation/Aggression - Week 4 - Mean: 13",
                        "Delusions - Week 4 - Mean: 9, SD: 4",
                        "Restlessness/Sleep: -0.11 (1.1)",
                        "Mood: -0.26 (1.1)",
                        "Psychosis: -0.22 (0.89)",
                        "Apathy/Appetite: +0.15 (2.1)",
                        "Mean change: \u22120.19, SD=5.3",
                        "8.6 \u00b1 5.1",
                        "NPI Total Score: -0.19 (5.3)",
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            },
            "c57b6880": {
                "total": 2,
                "corrected": 1,
                "label_comparator_data": "0.2 (12) ",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "46",
                        "54"
                    ],
                    "mean": [
                        "\u22126.2 \u00b1 8.7 (NPI \u2264 14)",
                        "-6.2 \u00b1 8.7",
                        "\u22122.9 \u00b1 8.0 (NPI > 14)",
                        "0.2 \u00b1 12.0",
                        "Insufficient evidence to draw a conclusion",
                        "\u22126.2 \u00b1 8.7",
                        "-2.9 \u00b1 8.0",
                        "0.9 \u00b1 3.0",
                        "\u22122.9 \u00b1 8.0"
                    ]
                },
                "label_intervention_data": "-1.3 (9.4)",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "46",
                        "17",
                        "19"
                    ],
                    "mean": [
                        "-3.2 \u00b1 11.7 (for baseline NPI \u2264 14)",
                        "-3.3 \u00b1 5.7 (for baseline NPI > 14)",
                        "\u22123.2 \u00b1 11.7",
                        "-3.3 \u00b1 5.7 (NPI > 14)",
                        "-3.3 \u00b1 5.7",
                        "-1.2 \u00b1 12.0 (placebo group), 0.2 \u00b1 12.0 (neuroleptic group)",
                        "Mean change in NPI total score for patients with baseline NPI > 14: -3.3 \u00b1 5.7",
                        "-1.2 \u00b1 12.0",
                        "\u22123.3 \u00b1 5.7",
                        "-3.2 \u00b1 11.7",
                        "-3.2 \u00b1 11.7 (NPI \u2264 14)",
                        "Mean change in NPI total score for patients with baseline NPI \u2264 14: -3.2 \u00b1 11.7",
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            }
        }
    },
    {
        "file": "outcomeinfo_PICO4c.json",
        "outcome uid": "ddb1d46f",
        "intervention": "Discontinuation of antipsychotics",
        "comparator": "Continuation of treatment",
        "outcome": "Global cognitive function",
        "data_type": "Continuous Data",
        "paper_data": {
            "4f4e0f75": {
                "total": 2,
                "corrected": 0,
                "label_comparator_data": "-16.5 (23.1)",
                "pred1_comparator_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "83",
                        "110",
                        "64",
                        "51"
                    ],
                    "mean": [
                        "-6.2",
                        "71.1",
                        "Mean outcome value: 1.8, Standard Deviation: 3.6",
                        "16.0",
                        "Insufficient evidence to draw a conclusion"
                    ]
                },
                "label_intervention_data": "-8.5 (13.4)",
                "pred1_intervention_data": {
                    "data_type": "Continuous Data",
                    "total": [
                        "82",
                        "51"
                    ],
                    "mean": [
                        "4.2 (standard deviation for SMMSE in the discontinuation group)",
                        "\u22125.7 (mean outcome value for SIB in the discontinuation group)",
                        "-5.7 \u00b1 14.2",
                        "Mean SIB score (Global cognitive function) for discontinuation group: 76.3, Standard Deviation: 20.8",
                        "76.3",
                        "14.2 (standard deviation for SIB in the discontinuation group)",
                        "\u22121.0 (mean outcome value for SMMSE in the discontinuation group)",
                        "20.8",
                        "Insufficient evidence to draw a conclusion"
                    ]
                }
            }
        }
    },
    {
        "paper_uid": "50df60b4",
        "label_data": {
            "number of patients randomized": "333"
        }
    },
    {
        "paper_uid": "f5076959",
        "label_data": {
            "number of patients randomized": "206"
        }
    },
    {
        "paper_uid": "0643f463",
        "label_data": {
            "number of patients randomized": "421"
        }
    },
    {
        "paper_uid": "44c2f905",
        "label_data": {
            "number of patients randomized": "62"
        }
    },
    {
        "paper_uid": "d21566cc",
        "label_data": {
            "number of patients randomized": "345"
        }
    },
    {
        "paper_uid": "c6e3bcaf",
        "label_data": {
            "number of patients randomized": "421"
        }
    },
    {
        "paper_uid": "baf84590",
        "label_data": {
            "number of patients randomized": "40 (AD patients: 8; PD+dementia 9; LBD: 23)"
        }
    },
    {
        "paper_uid": "2271541c",
        "label_data": {
            "number of patients randomized": "120 AD: 79; VaD: 34; Mixed AD-VaD: 7"
        }
    },
    {
        "paper_uid": "793447a7",
        "label_data": {
            "number of patients randomized": "58"
        }
    },
    {
        "paper_uid": "8c317dba",
        "label_data": {
            "number of patients randomized": "120"
        }
    },
    {
        "paper_uid": "64979d7f",
        "label_data": {
            "number of patients randomized": "230 Randomized to either haloperidol or risperidone"
        }
    },
    {
        "paper_uid": "39351825",
        "label_data": {
            "number of patients randomized": "55"
        }
    },
    {
        "paper_uid": "7e48dccc",
        "label_data": {
            "number of patients randomized": "36"
        }
    },
    {
        "paper_uid": "8f835918",
        "label_data": {
            "number of patients randomized": "110"
        }
    },
    {
        "paper_uid": "c57b6880",
        "label_data": {
            "number of patients randomized": "100"
        }
    },
    {
        "paper_uid": "135b5748",
        "label_data": {
            "number of patients randomized": "165"
        }
    },
    {
        "paper_uid": "aead9e3a",
        "label_data": {
            "number of patients randomized": "20"
        }
    },
    {
        "paper_uid": "1ad70ba1",
        "label_data": {
            "number of patients randomized": "34"
        }
    },
    {
        "paper_uid": "4f4e0f75",
        "label_data": {
            "number of patients randomized": "165"
        }
    },
    {
        "paper_uid": "0e34e33b",
        "label_data": {
            "number of patients randomized": "25"
        }
    }
]